Seeking Alpha

Citing an FDA warning letter and the company's revised FY13 guidance among other factors,...

Citing an FDA warning letter and the company's revised FY13 guidance among other factors, Moody's puts Hospira's (HSP -0.8%) long-term debt rating on review for downgrade. The ratings agency says "cash payouts associated with [HSP's new medical device] strategy, remediation costs, and the potential for lost sales once its branded injectible sedative, Precedex, loses patent protection" could hurt liquidity and tighten credit metrics.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)